Mi Jeong Kwon1,2, Jai Min Ryu3, Soo Youn Cho4, Seok Jin Nam3, Seok Won Kim3, Jeeyeon Lee5, Soo Jung Lee6, Ji-Young Park7, Ho Yong Park5, Sungjun Hong8, Kyunga Kim8,9, Jinil Han10, Youngho Moon10, Young Kee Shin11,12, Jeong Eon Lee3. 1. Vessel-Organ Interaction Research Center, College of Pharmacy, Kyungpook National University, Daegu, South Korea. 2. Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu, South Korea. 3. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. 4. Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. 5. Department of Surgery, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, South Korea. 6. Department of Oncology/Hematology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, South Korea. 7. Department of Pathology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, South Korea. 8. Department of Digital Health, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul, South Korea. 9. Statistics and Data Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, South Korea. 10. R&D Center, Gencurix Inc., Seoul, South Korea. 11. Laboratory of Molecular Pathology and Cancer Genomics, Research Institute of Pharmaceutical Sciences and College of Pharmacy, Seoul National University, Seoul, South Korea. 12. Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, South Korea.
Abstract
BACKGROUND: The prognostic or predictive value of commonly used multigene assays in young patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer is unclear. In this study, we assessed the prognostic value of the GenesWell BCT assay according to age group. METHODS: We identified patients with pN0-1, HR+/HER2- breast cancer in a prospective cohort of women who underwent surgery between 2005 and 2017. The GenesWell BCT assay was performed on tissue samples from selected patients. Distant metastasis-free survival (DMFS) and disease-free survival (DFS) were compared between the risk groups assigned by the BCT score. RESULTS: A total of 712 patients were eligible for analysis. The median follow-up time was 7.47 years. The BCT score was prognostic in patients aged ≤50 years (n = 404) and those aged >50 years (n = 308). In both age groups, the 10-year DMFS and DFS rates for patients classified as high risk by the BCT score were significantly lower than those for patients classified as low risk. A multivariate analysis revealed that the BCT score was an independent prognostic factor for DFS in patients aged ≤50 years (hazard ratio, 1.28; 95% CI, 1.05-1.56; P = 0.015), as well as those aged >50 years. CONCLUSION: The BCT score could be used to identify low-risk patients who will not benefit from adjuvant chemotherapy to treat HR+/HER2- early breast cancer regardless of age. A further prospective study to assess the prognostic and predictive value of the BCT score is required.
BACKGROUND: The prognostic or predictive value of commonly used multigene assays in young patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer is unclear. In this study, we assessed the prognostic value of the GenesWell BCT assay according to age group. METHODS: We identified patients with pN0-1, HR+/HER2- breast cancer in a prospective cohort of women who underwent surgery between 2005 and 2017. The GenesWell BCT assay was performed on tissue samples from selected patients. Distant metastasis-free survival (DMFS) and disease-free survival (DFS) were compared between the risk groups assigned by the BCT score. RESULTS: A total of 712 patients were eligible for analysis. The median follow-up time was 7.47 years. The BCT score was prognostic in patients aged ≤50 years (n = 404) and those aged >50 years (n = 308). In both age groups, the 10-year DMFS and DFS rates for patients classified as high risk by the BCT score were significantly lower than those for patients classified as low risk. A multivariate analysis revealed that the BCT score was an independent prognostic factor for DFS in patients aged ≤50 years (hazard ratio, 1.28; 95% CI, 1.05-1.56; P = 0.015), as well as those aged >50 years. CONCLUSION: The BCT score could be used to identify low-risk patients who will not benefit from adjuvant chemotherapy to treat HR+/HER2- early breast cancer regardless of age. A further prospective study to assess the prognostic and predictive value of the BCT score is required.
Authors: Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark Journal: N Engl J Med Date: 2004-12-10 Impact factor: 91.245
Authors: Maureen Cronin; Mylan Pho; Debjani Dutta; James C Stephans; Steven Shak; Michael C Kiefer; Jose M Esteban; Joffre B Baker Journal: Am J Pathol Date: 2004-01 Impact factor: 4.307
Authors: Gyungyub Gong; Mi Jeong Kwon; Jinil Han; Hee Jin Lee; Se Kyung Lee; Jeong Eon Lee; Seon-Heui Lee; Sarah Park; Jong-Sun Choi; Soo Youn Cho; Sei Hyun Ahn; Jong Won Lee; Sang Rae Cho; Youngho Moon; Byung-Ho Nam; Seok Jin Nam; Yoon-La Choi; Young Kee Shin Journal: Sci Rep Date: 2017-03-28 Impact factor: 4.379
Authors: Maj-Britt Jensen; Anne-Vibeke Lænkholm; Torsten O Nielsen; Jens Ole Eriksen; Pernille Wehn; Tressa Hood; Namratha Ram; Wesley Buckingham; Sean Ferree; Bent Ejlertsen Journal: Breast Cancer Res Date: 2018-07-27 Impact factor: 6.466